Rhumbline Advisers Increases Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Rhumbline Advisers lifted its holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 10.8% in the 2nd quarter, Holdings Channel reports. The firm owned 55,220 shares of the company’s stock after acquiring an additional 5,360 shares during the period. Rhumbline Advisers’ holdings in ALX Oncology were worth $333,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ALXO. Privium Fund Management B.V. bought a new stake in ALX Oncology during the second quarter valued at about $2,271,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of ALX Oncology by 31.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 104,966 shares of the company’s stock valued at $633,000 after purchasing an additional 25,199 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of ALX Oncology by 413.8% in the 1st quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock valued at $254,000 after purchasing an additional 18,360 shares during the last quarter. Finally, Redmile Group LLC raised its holdings in shares of ALX Oncology by 18.2% in the first quarter. Redmile Group LLC now owns 4,326,509 shares of the company’s stock worth $48,241,000 after buying an additional 667,245 shares during the period. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Trading Up 5.3 %

Shares of NASDAQ:ALXO opened at $1.97 on Friday. ALX Oncology Holdings Inc. has a 12-month low of $1.76 and a 12-month high of $17.83. The business’s fifty day simple moving average is $2.91 and its 200-day simple moving average is $8.34. The company has a market capitalization of $103.76 million, a PE ratio of -0.53 and a beta of 1.01. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.01. As a group, equities research analysts predict that ALX Oncology Holdings Inc. will post -3.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ALXO. Lifesci Capital downgraded ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. UBS Group reduced their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a report on Tuesday, August 13th. Finally, Stifel Nicolaus restated a “hold” rating and set a $3.00 price objective (down from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Insider Buying and Selling

In related news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $7.90, for a total value of $158,000.00. Following the completion of the sale, the insider now directly owns 593,447 shares in the company, valued at approximately $4,688,231.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 28,398 shares of company stock worth $200,043 in the last three months. Corporate insiders own 33.40% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.